Chips power the modern world, and the global semiconductor shortage showed their impact. This graphic highlights the evolution of the chip-tech field.
Innovative coronavirus disease2019(COVID-19) vaccines, with elevated global manufacturing capacity, enhanced safety and efficacy, simplified dosing regimens, and distribution that is less cold chain-dependent, are still global imperatives for tackling the ongoing pandemic. A previous phase I trial indicated that the recombinant COVID-19 vaccine (V-01), which contains a fusion protein (IFN-PADRE-RBD-Fc dimer) as its antigen, is safe and well tolerated, capable of inducing rapid and robust immune responses, and warranted further testing in additional clinical trials. Herein, we aimed to assess the immunogenicity and safety of V-01, providing rationales of appropriate dose regimen for further efficacy study.
Methods:
A randomized, double-blind, placebo-controlled phase II clinical trial was initiated at the Gaozhou Municipal Centre for Disease Control and Prevention (Guangdong, China) in March 2021. Both younger (n = 440; 18–59 years of age) and older (n = 440; ≥60 years of age) adult participants in this trial were sequentially recruited into two distinct groups: two-dose regimen group in which participants were randomized either to follow a 10 or 25 μg of V-01 or placebo given intramuscularly 21 days apart (allocation ratio, 3:3:1, n = 120 120, 40 for each regimen, respectively), or one-dose regimen groups in which participants were randomized either to receive a single injection of 50 μg of V-01 or placebo (allocation ratio, 3:1, n = 120 40, respectively). The primary immunogenicity endpoints were the geometric mean titers of neutralizing antibodies against live severe acute respiratory syndrome coronavirus 2 and specific binding antibodies to the receptor binding domain (RBD).
https://youtube.com/watch?v=zHtgTu4qjUw
Scientists recently broke their own laser-fusion record! But they must replicate their success soon to preserve research in thermonuclear weapons.
Circa 2019
STRANGER Things has attracted a global audience of over 20million viewers who love the show for its eerie plot lines involving secret government experiments and monsters from other dimensions.
But the alleged real-life stories that inspired the Netflix show — which was confirmed for a forth series on Monday - are more terrifying than anything in the fictional town of Hawkins, where the series is set.
The Prime Minister, Boris Johnson, has reiterated that the Taliban must meet certain terms if they want frozen funds to be released to them.
Addressing several pots of money that have been frozen, the Prime Minister once again insisted that the Taliban must meet the West’s demands in order to access the funds.
“It’s really important that we don’t think of structures in the brain as monolithic,” said Gowrishankar. “There’s lots of little nuance in brain. How plastic it is. How it’s wired. This finding is showing one way how differences can play out.”
Researchers alter two of five genes responsible for vision in Aedes aegypti to make human targets less visible to these flying insects.
How do you say that again?
Researchers alter two of five genes responsible for vision in Aedes aegypti to make human targets less visible to these flying insects.
New research from the University of Virginia School of Medicine quantifies the antibody response generated by the Pfizer and Moderna COVID vaccines. The findings are some of the earliest to compare the two vaccines’ antibody responses head-to-head. The notable finding was that antibody levels in recipients of the Moderna vaccine were slightly higher than in recipients of Pfizer.
The researchers caution against drawing conclusions about the vaccines’ effectiveness based on the antibody numbers. Both vaccines, they say, have performed exceptionally after having been given to millions of people around the world. The new results are just a small piece in a much larger puzzle as scientists seek to determine if one vaccine may be superior for certain demographics.
“The thing that will be interesting is figuring out if measuring antibody levels ends up being a good marker of vaccine protection,” UVA immunologist Dr. Jeffrey Wilson said. “At the moment, we don’t know for sure.”
Continue reading “COVID-19 Research Quantifies Antibody Response to Pfizer, Moderna Vaccines” »
ASML’s latest EUV lithography machine may be able to kill two birds with one stone! Reviving Moore’s law, the second solving the chip shortage.
The rapid commercialization of space and the establishment of the U.S. Space Force have created ideal conditions for change in the national security space business, says Steve Isakowitz, CEO of the Aerospace Corp. and former president of Virgin Galactic.
Aerospace, based in El Segundo, California, is a federally funded research and development center focused on analysis and assessment of space programs for the Defense Department, NASA and the National Reconnaissance Office.
In an interview with SpaceNews, Isakowitz says unprecedented opportunities are emerging for national security space organizations to capture commercial innovation. Defense programs won’t transform overnight, he says, but change is definitely in the air.
